BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27031899)

  • 1. Bloodstream infection with Oligella ureolytica: a case report and review of the literature.
    Pagotto A; Merluzzi S; Pillinini P; Valeri M
    Infez Med; 2016; 24(1):58-61. PubMed ID: 27031899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood stream infection by an emerging pathogen Oligella ureolytica in a cancer patient: case report and review of literature.
    Baruah FK; Jain M; Lodha M; Grover RK
    Indian J Pathol Microbiol; 2014; 57(1):141-3. PubMed ID: 24739856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bloodstream infection with Oligella ureolytica in a newborn infant: a case report and review of the literature.
    Demir T; Celenk N
    J Infect Dev Ctries; 2014 Jun; 8(6):793-5. PubMed ID: 24916881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligella ureolytica Bacteremia in Elderly Woman, United States.
    Simmons T; Fennelly E; Loughran D
    Emerg Infect Dis; 2015 Jul; 21(7):1271-3. PubMed ID: 26079071
    [No Abstract]   [Full Text] [Related]  

  • 5. Rahnella aquatilis bacteremia in a patient with relapsed acute lymphoblastic leukemia.
    Carinder JE; Chua JD; Corales RB; Taege AJ; Procop GW
    Scand J Infect Dis; 2001; 33(6):471-3. PubMed ID: 11450870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delftia lacustris septicemia in a pheochromocytoma patient: case report and literature review.
    Sohn KM; Baek JY
    Infect Dis (Lond); 2015 May; 47(5):349-53. PubMed ID: 25712727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
    Solomkin JS; Yellin AE; Rotstein OD; Christou NV; Dellinger EP; Tellado JM; Malafaia O; Fernandez A; Choe KA; Carides A; Satishchandran V; Teppler H;
    Ann Surg; 2003 Feb; 237(2):235-45. PubMed ID: 12560782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety evaluation of piperacillin/tazobactam in very low birth weight infants.
    Berger A; Kretzer V; Apfalter P; Rohrmeister K; Zaknun D; Pollak A
    J Chemother; 2004 Apr; 16(2):166-71. PubMed ID: 15216952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature.
    D'Agostino C; Rhodes NJ; Skoglund E; Roberts JA; Scheetz MH
    J Infect Chemother; 2015 Oct; 21(10):742-6. PubMed ID: 26143049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
    Harris PN; Peleg AY; Iredell J; Ingram PR; Miyakis S; Stewardson AJ; Rogers BA; McBryde ES; Roberts JA; Lipman J; Athan E; Paul SK; Baker P; Harris-Brown T; Paterson DL
    Trials; 2015 Jan; 16():24. PubMed ID: 25623485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ; Cappelletty DM;
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of Robinsoniella peoriensis bacteremia during using piperacillin-tazobactam.
    Furuya K; Ito K; Sugiyama K; Makio S; Shimada T
    J Infect Chemother; 2023 Sep; 29(9):913-915. PubMed ID: 37263500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nosocomial bacteremia and catheter infection by Bacillus cereus in an immunocompetent patient.
    Hernaiz C; Picardo A; Alos JI; Gomez-Garces JL
    Clin Microbiol Infect; 2003 Sep; 9(9):973-5. PubMed ID: 14616690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raoultella planticola bacteraemia.
    Hu AY; Leslie KA; Baskette J; Elsayed S
    J Med Microbiol; 2012 Oct; 61(Pt 10):1488-1489. PubMed ID: 22820690
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
    Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
    Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
    Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
    PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.